CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)
ConditionDLBCL
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRuijin Hospital
About this trial
This was an open, multicenter clinical study of newly treated DLBCL patients with TP53 mutations and del(17p) with IPI\>1. Participants who met the inclusion/exclusion criteria signed informed consent and received 1 course of R-CHOP, followed by the remaining 5 cycles courses of chidamide and decitabine combined with a standard-dose R-CHOP regimen.
Eligibility criteria
Qualifiers
1. Histologically confirmed diffuse large B-cell lymphoma with CD20 positive;
2. Pathologically confirmed a combination of TP53 mutation and del(17p);
3. Age ≥ 18 years old, ≦75 years old;
4. ECOG physical status score of 0, 1 or 2;
Disqualifiers
1. Have previously received systemic or local treatment including chemotherapy;
2. Previously received autologous stem cell transplantation;
3. Previous history of other malignant tumors, except skin basal cell carcinoma and cervical carcinoma in situ;
4. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases and other diseases;
Trial design
Treatments tested in this trial
- CDR-CHOP
Treatment groups
34 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov